Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001955583 | SCV002220344 | uncertain significance | not provided | 2021-08-14 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with arginine at codon 216 of the EPB42 protein (p.Gly216Arg). The glycine residue is weakly conserved and there is a moderate physicochemical difference between glycine and arginine. This variant is present in population databases (rs199634098, ExAC 0.02%). This variant has not been reported in the literature in individuals affected with EPB42-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt EPB42 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV003146396 | SCV003833514 | uncertain significance | Hereditary spherocytosis type 5 | 2022-11-23 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001955583 | SCV004227386 | uncertain significance | not provided | 2022-11-14 | criteria provided, single submitter | clinical testing | BP4_strong, PM2 |